Neoplasia/BPH

	Insurance Disparity in Novel Hormonal Therapy Initiation in Patients With Metastatic Hormone-Sensitive Prostate Cancer: Medicare Advantage Versus Traditional Medicare. JCO Oncol Pract Jafry B, Lu CA, Ji J, Hu X, Bhanvadia R, Qin Q, Han X, Nipp RD, Shih YT, Yabroff KR, Zhang T, Jiang C. PMID: 42024832 [PubMed - as supplied by publisher]
	Evolution of survival outcomes in robot-assisted radical cystectomy over 20 years of experience in a high-volume tertiary robotic center. Minerva Urol Nephrol Resca S, Morra S, Frego N, Tamburini S, Ticonosco M, Pissavini A, Mourullo AN, Barletta F, Lambert E, D'Hondt F, DE Groote R, DE Naeyer G, Mottrie A. PMID: 42023750 [PubMed - indexed for MEDLINE]
	Real-world multicenter adherence to international guidelines in the management of upper tract urothelial carcinoma: insights from the ROBUUST 2.0 Registry. Minerva Urol Nephrol Ferriero M, Tuderti G, Proietti F, Chiacchio G, Bignante G, Wu Z, Wang L, Margulis V, Bhanvadia R, Abdollah F, Cusumano NB, Antonelli A, Ditonno F, Veccia A, Singla N, Brönimann S, Derweesh IH, Puri D, Meagher MF, Rais-Bahrami S, Moon SC, Ferro M, DE Cobelli O, Porpiglia F, Amparore D, Checcucci E, Lee R, Correa AF, Eun DD, Gonzalgo ML, Nativ OF, Perdonà S, Tufano A, Eraky A, Mehrazin R, Yong C, Sundaram CP, Yoshida T, Kinoshita H, Ghoreifi A, Moghaddam FS, Djaladat H, Autorino R, Simone G. PMID: 42023749 [PubMed - indexed for MEDLINE]
	Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study). Minerva Urol Nephrol Maruzzo M, Poprach A, Buti S, Bamias A, Zakopoulou R, DE Giorgi U, Kucharz J, Formisano L, Buttner T, Zucali PA, Li H, Incorvaia L, Kopp RM, Messina C, Kopecky J, Fornarini G, Landmesser J, Rebuzzi SE, Nasso C, Fay AP, Bhuva D, Pinto A, Buchler T, Pichler R, Kanesvaran R, Soares A, Massari F, Monteiro FS, Dos Santos Filho IA, Porta C, Basso U, Santoni M. PMID: 42023748 [PubMed - indexed for MEDLINE]
	Pharmacology, efficacy and safety of different extracts of Serenoa repens in patients with lower urinary tract symptoms and benign prostatic hyperplasia: a narrative review. Minerva Urol Nephrol DE Nunzio C, Lombardo R, Franco A, Turchi B, Cicione A, Gacci M, Gravas S. PMID: 42023747 [PubMed - indexed for MEDLINE]
	Detrimental effect of delayed or incomplete BCG protocols administration after trans-urethral tumor resection in patients with non-muscle-invasive bladder cancer: a systematic review. Minerva Urol Nephrol DI Trapani E, Lo Giudice A, Mazzone E, Dell'oglio P, Sorce G, Luzzago S, Mistretta FA, LA Croce G, Piccinelli M, DI Trapani D, Moschini M, Galfano A, Montorsi F, Briganti A, Abdollah F, DE Cobelli O, Musi G. PMID: 42023746 [PubMed - indexed for MEDLINE]
	Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in people undergoing radical cystectomy. Cochrane Database Syst Rev Lee CH, Shepherd A, Sathianathen N, Hwang JE, Hwang EC, Kim MH, Narayan V, Jung JH, Dahm P. PMID: 42023708 [PubMed - indexed for MEDLINE]
	Characteristics and therapeutic resistance mechanisms of the prostate cancer immune microenvironment: a comprehensive analysis from bench to clinic. Front Pharmacol Li J, Wang X, Tang X. PMID: 42022555 [PubMed]
	Comparison of the effects of exercise-based interventions on cardiometabolic health and fatigue in men with prostate cancer receiving androgen deprivation therapy: A network meta-analysis. Asia Pac J Oncol Nurs Quan L, Zhang Y, Wu S, Hou S, Li K, Tian W, Wang W. PMID: 42022295 [PubMed]
	Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naÃ¯ve non-muscle invasive bladder cancer: Systematic review and meta-analysis. BJUI Compass Titus RS, Riveros C, Velasquez EL, Nguyen DD, Somawardana S, Singh A, Kaushik D, Sonpavde G, Zlotta A, Kulkarni G, Sridhar SS, Wallis CJD, Satkunasivam R. PMID: 42022227 [PubMed]
	Diagnostic and therapeutic challenges in intradiverticular bladder carcinoma: A case report. Urol Case Rep Manoj A, Chakraborty S, Kantha A, Pandey M. PMID: 42021970 [PubMed]
	Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study. Cancer Commun (Lond) Li H, Chen M, Huang R, Rong Q, Hao J, Zheng Q, Su Y, Shu D, Zhang Y, Yang W, Lei X, Cai Y, Xue C, An X, Shi Y. PMID: 42021969 [PubMed - indexed for MEDLINE]
	Rates and Predictors of Persistent LUTS Medication Use After Laser Enucleation of the Prostate. Low Urin Tract Symptoms Filzmayer M, Traumann MI, Humke C, Müller MJ, Mandel PC, Kluth LA, Becker A, Chun FK, Kosiba M. PMID: 42021565 [PubMed - indexed for MEDLINE]
	Correction: Vegetable intake and the risk of bladder cancer in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study. BMC Med Yu EY, Wesselius A, Mehrkanoon S, Goosens M, Brinkman M, van den Brandt P, Grant EJ, White E, Weiderpass E, Le Calvez-Kelm F, Gunter MJ, Huybrechts I, Riboli E, Tjonneland A, Masala G, Giles GG, Milne RL, Zeegers MP. PMID: 42021259 [PubMed - in process]
	First-Line Therapy for Advanced Renal Cell Carcinoma: Score-Matched Analysis of Dual Combination Immunotherapy versus Combination of Tyrosine Kinase Inhibitors and Immunotherapy in the TOURS Multicenter Study. Target Oncol Watanabe H, Nakane K, Nukaya T, Naiki T, Yasui T, Takahara K, Koie T, Inamoto T, Miyake H. PMID: 42020851 [PubMed - as supplied by publisher]
	[(68)Ga]Ga-NY104 PET/CT for the detection of clear cell renal cell carcinoma in presurgical patients with renal masses (NYCRPS): a prospective, single-centre, phase II study. Eur J Nucl Med Mol Imaging Yan X, Zheng G, Wang J, Liu M, Chen J, Xie Y, Fu C, Zhang Y, Zhu W, Huo L. PMID: 42020811 [PubMed - as supplied by publisher]
	Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients. Nat Commun Heumann P, Aguado-Barrera ME, Jandu HK, Azria D, Briers E, Bultijnck R, Chang-Claude J, Choudhury A, Dunning AM, Fachal L, Fuentes-Ríos O, Gómez-Caamaño A, Gutiérrez-Enríquez S, Kaaks R, Kerns SL, Lambrecht M, Romero JCR, Rosenstein BS, De Ruysscher D, Schmidt ME, Sperk E, Stobart H, Symonds RP, Veldeman L, Veldwijk MR, Ward T, Webb A, West CML, Rancati T, Rattay T, Vega A, REQUITE Consortium, Talbot CJ, Seibold P. PMID: 42020408 [PubMed - indexed for MEDLINE]
	Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials. Eur Urol Oncol Vauchier C, Thibault C, Velev M, Becker O, Guillaume Z, Ashton E, Zaibet S, Berthou H, Courtinat F, Gervais C, Rochand A, Robbrecht D, Oudard S, Auclin E. PMID: 42020286 [PubMed - as supplied by publisher]
	Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active surveillance versus intravesical bacillus Calmette-GuÃ©rin for high-grade T1 bladder cancer with negative second transurethral resection: the randomized noninferiority phase 3 JCOG1019 trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. Eur Urol Lobo N, Contieri R, Mertens L, Kamat AM. PMID: 42020257 [PubMed - as supplied by publisher]
	Phase 1 Dose-Escalation Study of [(225)Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry. J Nucl Med Ling SW, Konijnenberg M, Segbers M, Hooijman E, Koolen S, de Blois E, De Jong LC, van Puffelen A, de Lussanet de la Sabloniere Q, Bruchertseifer F, Chilug EL, Morgenstern A, van der Veldt A, Brabander T. PMID: 42020144 [PubMed - as supplied by publisher]

Articles 1 - 20 / 187264

Page 1 of 9364



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy